1. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients. (28th August 2021) Authors: Ligumsky, Hagai; Safadi, Esraa; Etan, Tal; Vaknin, Noam; Waller, Manuel; Croll, Assaf; Nikolaevski-Berlin, Alla; Greenberg, Inbal; Halperin, Tami; Wasserman, Asaf; Galazan, Lior; Arber, Nadir; Wolf, Ido Journal: Journal of the National Cancer Institute Issue: Volume 114:Number 2(2022) Page Start: 203 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Issue 5 (May 2021) Authors: Waissengrin, Barliz; Agbarya, Abed; Safadi, Esraa; Padova, Hagit; Wolf, Ido Journal: Lancet oncology Issue: Volume 22:Issue 5(2021) Page Start: 581 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗